SynthesisFrontiers in endocrinology2025
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic kidney disease: a meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial.Diabetes, obesity & metabolism · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease is a major cause of end-stage renal disease. Herein, we aimed to assess the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with diabetic kidney disease. Methods: PubMed, Embase, and Web of Science databases were searched for eligible randomized clinical trials (RCTs) published up to July 2024. Effect sizes were summarized as risk ratios (RR) or weighted mean differences (WMD) with 95% confidence intervals (CI). Statistical analyses were performed using Stata. Results: Fifteen studies (24463 patients) were included in the meta-analysis. The results of the meta-analysis showed that compared with the control group, SGLT2 inhibitor intervention could reduce the estimated glomerular filtration rate (WMD=-2.47; 95% CI: -3.18, -1.76), systolic blood pressure (WMD=-4.09; 95% CI: -4.97 to -3.21), diastolic blood pressure (WMD=-2.47; 95% CI: -3.06 to -1.88), and glycated hemoglobin (WMD=-0.27; 95% CI: -0.38, -0.17). Moreover, there was no significant difference between the SGLT2 inhibitor and control groups in terms of the incidence of overall adverse event, urinary tract infection, bone fracture and hypoglycemia. However, the incidence of genital infection and diabetic ketoacidosis in the SGLT2 inhibitor group was higher than that in the control group. Conclusion: Our study confirms the beneficial effects in diabetic kidney disease patients, while also demonstrating a higher risk of genital infections and diabetic ketoacidosis in the SGLT2 inhibitor group compared to controls.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.